CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of data that demonstrate anti-angiogenic properties of TM601. The findings from this mechanism of action study show that in addition to the high affinity tumor binding activity of TM601 that the compound may be an effective inhibitor of angiogenesis and tumor progression. The abstract was presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA by Dr. Douglas Jacoby, Senior Director of Research and Development at TransMolecular in a poster session on April 13, 2008.
